Periodic Reporting for period 2 - RESPIRE (Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD))

Palobiofarma is a Spanish clinical stage biotech company focused on discovering and developing innovative treatments that modulate adenosine receptors. Our lead compound, PBF-680, is being developed as a first-in-class, disease-modifying therapy for chronic obstructive...